Vijay Kumar Damodhar , Rukhsana Mahiboob Pinjari
International Journal of Medical, Pharmacy and Drug Research(IJMPD), Vol-7,Issue-5, October - December 2023, Pages 8-14 ,
Download | Downloads : 2 | Total View : 251
Article Info: Received: 08 Aug 2023; Received in revised form: 13 Sep 2023; Accepted: 21 Sep 2023; Available online: 30 Sep 2023
Gastroesophageal reflux disease (GERD) and peptic ulcers are prevalent gastrointestinal disorders that significantly impact the quality of life of affected individuals. Lafutidine, a histamine H2-receptor antagonist, has demonstrated effectiveness in managing these conditions. However, its short gastric residence time limits its therapeutic efficacy. To address this limitation, we aimed to formulate and evaluate a floating in situ gel of Lafutidine for prolonged gastric retention and enhanced therapeutic outcomes. In vivo studies were conducted on albino Wistar rats to assess the pharmacokinetic parameters and gastric residence time. The pharmacokinetic evaluation demonstrated that the floating in situ gel exhibited improved Lafutidine bioavailability compared to the conventional dosage form. Gastric residence time was significantly extended, enhancing Lafutidine's therapeutic efficacy. Overall, the formulation and evaluation of the floating in situ gel of Lafutidine demonstrated its potential as an effective drug delivery system for the management of GERD and peptic ulcers. The extended gastric retention and enhanced bioavailability of Lafutidine make this formulation a promising option for improving patient compliance and therapeutic outcomes in the treatment of these gastrointestinal disorders. Further clinical studies are warranted to establish its clinical efficacy and safety profile.